⚠️ If You Compete: Anti-Doping Comes First
This section is first because it is the one with a sanction attached, and because no other page about masters athletes and IV therapy seems to mention it.
If you compete in any sport under the World Anti-Doping Code — including age-group and masters championships, which are routinely tested — three parts of the Prohibited List apply directly to the treatments marketed to you: [11]
1. The infusion itself may be a prohibited method. Section M2.2 prohibits intravenous infusions and/or injections of more than 100 mL per 12-hour period, except those legitimately received in the course of hospital treatments, surgical procedures or clinical diagnostic investigations. An elective wellness infusion programme is none of those three. A standard IV bag exceeds 100 mL.
2. Growth factors are prohibited substances. Section S2 covers peptide hormones, growth factors, related substances and mimetics. Clinics offering "growth factor treatments" frequently do not name the agent — which means you cannot check it against the List.
3. Blood manipulation. Section M1 covers manipulation of blood and blood components. PRP's status has changed over the years, which is exactly why it must be checked against the current List rather than assumed.
Strict liability applies. Under the Code, you are responsible for what is in your body regardless of intent, and regardless of what a clinic told you. "I didn't know it was an infusion" is not a defence.
What to actually do, before you book anything:
- Download the current year's Prohibited List — it is revised annually and categories move.
- Ask the clinic, in writing, for every substance and volume you would receive, including IV fluid volumes.
- Check each against the List, and use your national anti-doping organisation's substance-checking service.
- If something is prohibited and medically justified, apply for a Therapeutic Use Exemption in advance. Retroactive TUEs are granted only in narrow circumstances.
- If a clinic cannot or will not itemise what they are giving you, that answers the question.
⚠️ This page describes the structure of the List as a starting point, not as clearance. Verify against the current List and your own federation's rules.
What Actually Changes After 40
Less than you might think — and the reason matters
The most useful finding for masters athletes is also the most frequently ignored. A narrative review of ageing and recovery kinetics concluded that the effect of age on performance and recovery may be smaller than originally suggested, and that increasing sedentary lifestyles appear to play a larger role in the decrements masters athletes observe. [1]
That is good news, and it has a practical consequence: a substantial share of what feels like ageing is detraining, which is modifiable.
Muscle power does decline with age — records from World Masters Athletes show it beginning around age 30 and falling roughly linearly thereafter. [2]But the same body of work found that lifelong active seniors have more muscle bulk and better-preserved slow fibre grouping than sedentary peers, which is direct evidence that continued training preserves the neuromuscular architecture that ageing erodes. [2]
Tendon is the tissue that genuinely changes
Tendinopathy affects approximately 25% of the adult population, and prevalence rises with age. [3]
Three changes are well described:
Fewer, less functional tendon stem/progenitor cells. In laboratory work using 3D tendon organoids grown from human Achilles biopsies (4 young donors, 9 aged donors), aged cells showed "profound phenotypic changes with declined cellular functions that can be linked to the known increase in complications during tendon healing process in elderly patients." [4]This is an in-vitro finding — it describes cells in a dish, not a treatment.
Stiffer, abnormally crosslinked collagen. Advanced glycation end-products accumulate, stiffening tissue while making it more vulnerable to microdamage. [3]
A blunted healing response. In a senescence-accelerated mouse model of collagenase-induced tendon injury, aged tendons showed higher IL-6, increased MMP-9 and reduced tissue inhibitor expression. [5]This is a mouse study, and it describes a mechanism, not a human outcome.
Bone, in masters runners
Bone stress injuries in masters runners appear to combine features of overuse from insufficient recovery and failure of bone weakened by age-related change — which is why load management matters more, not less, with age. [6]
What Actually Works
This section comes before the treatment discussion because the evidence is stronger here, and because it is what most masters athletes are looking for.
Progressive tendon loading — first-line for the injuries this audience gets
The injuries listed later in this article are overwhelmingly tendinopathies. Loading is the primary evidence-based treatment for them.
A systematic review of 32 studies of Achilles and patellar tendinopathy loading programmes compared isolated eccentric training, eccentric-concentric progressing to eccentric, and heavy-slow resistance loading. [8]Loading works, and the review is honest about its limits: up to 45% of patients may not respond to isolated eccentric training alone, which is a reason to progress and vary the loading protocol with a physiotherapist — not a reason to abandon it for an infusion.
Tendon adapts to mechanical load. That is the mechanism, it is well established, and it is free.
Resistance training and cardiorespiratory fitness
Beyond the injured tendon, two things carry outcome data that dwarf anything in regenerative medicine.
Physical activity, including strength work. WHO's 2020 guidelines recommend 150–300 minutes of moderate or 75–150 minutes of vigorous aerobic activity per week, plus muscle-strengthening activity on two or more days per week, and note that some activity is better than none across all adult age groups. [9]
Cardiorespiratory fitness. In 122,007 patients undergoing exercise treadmill testing, higher fitness was associated with lower long-term mortality with no observed upper limit of benefit; the risk associated with the lowest fitness quintile was comparable in magnitude to established clinical risk factors. [10]This is observational and cannot prove causation, but the gradient is consistent and the dataset is very large.
The unglamorous parts
Sleep and protein intake genuinely matter for recovery after 40, and both are usually the first things to slip in a busy training life. Load management — progressing volume gradually, respecting a tendon that is complaining — prevents more lost seasons than any intervention on this page.
Get a diagnosis before a treatment
A stiff shoulder after tennis is not one thing. Rotator cuff tendinopathy, a partial or full-thickness tear, and subacromial pain each have different management, and a full-thickness tear in a masters athlete is a different problem from tendinopathy. [7]A sports physiotherapist or sports medicine physician can distinguish them; an infusion cannot.
Sport-Specific Injury Patterns
Golf
The swing generates large rotational forces through spine, shoulders and wrists:
- Rotator cuff tendinopathy (leading shoulder)
- Lower back disc degeneration
- Medial epicondylalgia (golfer's elbow)
- Hip and knee degeneration from walking 18 holes
Tennis
Explosive movement, rapid direction change, repetitive overhead loading:
- Rotator cuff injuries in the serving shoulder
- Lateral epicondylalgia (tennis elbow)
- Achilles tendinopathy
- Patellar tendinopathy
Rotator cuff injuries are common in masters athletes, particularly overhead athletes, with risk rising alongside age, degeneration, activity volume and loss of motion. [7]
Running and cycling
- Achilles and patellar tendinopathy
- Bone stress injuries [6]
- Iliotibial band syndrome
- Hip and knee osteoarthritis
Skiing
High-impact loading with rapid eccentric contraction:
- ACL and MCL injuries
- Meniscal tears
- Quadriceps and hamstring strains
- Skier's thumb
Risk rises when conditioning has been inconsistent or after a layoff — which is a load-management problem, and therefore a solvable one.
What the Cell Therapy Evidence Actually Shows
Mesenchymal stromal cells act mainly by secreting signalling factors that modulate the local tissue environment. They are cleared within days and do not rebuild tissue directly.
Here is the evidence, at its true strength.
Tendon
The most-cited study is a follow-up of patients with chronic patellar tendinopathy treated with bone marrow-derived MSCs injected directly into the tendon. [13]Its details matter:
- Design: cohort study, level of evidence 2 — not a randomised trial
- n = 20 total — 10 originally treated with MSCs, 10 originally given leukocyte-poor PRP and then crossed over to MSCs
- Dose: 20 million cells, injected locally into the tendon
- At 12 months the original MSC group (n = 10) showed continued improvement in tendon structure on MRI (P < .0001) and in pain scores (P < .05) compared with their own baseline — there was no untreated control group at that timepoint
- In the crossover group, the improvement was not statistically significant on the pain scale for sports activity (P = .139)
That last point deserves emphasis on a page for athletes: the sport-specific outcome did not reach significance in half the cohort.
A systematic review of MSCs for tendon and ligament injury concluded they "might be a good alternative option for athletes" — while noting that it accepted papers of all evidence levels without following strict PRISMA guidelines because so few exist, and that "in human clinical trials there have been only a few studies published so far." [14]
A 2025 narrative review found PRP shows sustained pain and function improvement in chronic tendinopathies, whereas MSCs show promise in enhancing graft integrity in ligament reconstruction — that is, as an adjunct to surgery, not a replacement for it. [15]
Muscle
The muscle evidence frequently cited is a controlled laboratory study in 36 mice. Bone marrow MSCs were injected intramuscularly at doses of 125,000 to 250,000 cells into a contusion model, and regenerating myofibre counts and contractile strength were measured at 28 days. [12]
It is a well-conducted animal study. It is not evidence about return-to-play in humans, and the doses and route bear no relationship to an intravenous infusion of 100 million cells.
Exosomes
MSC-derived extracellular vesicles are an active research area with genuine preclinical results. [16]No human trial has tested whether giving exosomes before a cell infusion improves the outcome of that infusion. A sequencing claim requires a study that varies the sequence, and none exists.
On dose — more is not established as better
Clinics commonly offer higher cell counts as a premium option. The published dose-finding data does not support this. An analysis of 914 MSC trials found effective intravenous doses clustering at *100–150 million, with lower and higher doses less effective. [17]In a randomised placebo-controlled trial, a 100-million dose improved physical performance while 200 million did not*. [18]
If a clinic offers you more cells for more money, ask which study shows more is better.
The gap nobody bridges
The tendon evidence uses local injection into the injured tendon. Most commercial programmes sell intravenous infusion. These are not the same intervention: after an IV infusion, the majority of cells are trapped in the lungs on first pass and do not reach a patellar tendon. A local injection study cannot support a systemic infusion, at any dose.
Safety
Who should not receive intravenous cell therapy:
- Anyone with an active or recently treated malignancy, or under surveillance
- Anyone on immunosuppressive therapy, or with an active infection
- Anyone pregnant or breastfeeding
- Anyone competing under anti-doping rules who has not checked the current Prohibited List and, where needed, obtained a TUE
- Anyone whose injury has not been properly diagnosed
What the safety evidence covers. A systematic review of intravascular MSC therapy identified 36 studies with 1,012 participants (8 randomised, enrolling 321). Meta-analysis found no association with acute infusional toxicity, organ system complications, infection, death or malignancy — and a significant association with transient fever (OR 16.82, 95% CI 5.33–53.10). [18]Reassuring on short-term serious harm; not a basis for claims about repeated infusions in healthy athletes, which nobody has studied.
Ozone therapy and unnamed "growth factor treatments", sometimes bundled into athlete protocols, carry their own risks and their own anti-doping implications. Ask what they are.
Is This For You?
There is no evidence-based candidacy profile for cell therapy in masters athletes, because the trials that would define one have not been done. So rather than criteria, here are the questions worth asking.
Before considering any treatment:
- Do I have a diagnosis, from someone who examined me?
- Have I done a structured loading programme, progressed properly, for long enough? Tendon rehabilitation is measured in months, not weeks.
- Is my training load, sleep and protein intake actually where I think it is?
- Do I compete under anti-doping rules?
If you are still considering treatment:
- What is the evidence in my specific injury, in humans, with a control group?
- What dose and route, and which study supports that combination?
- What outcome will we measure, when, and what would count as failure?
- What is your adverse event rate, over how many patients?
⚠️ On the promise of feeling like your younger self. Some decline with age is real and not fully reversible, and an athlete who trains well, sleeps well and loads sensibly may still be slower at 50 than at 30. That is not a failure to optimise. Any page that implies otherwise is setting you up to blame yourself — or to keep buying.